

Table e-1. Overview of the results of the application of THC on pain assessments in dementia patients

	n	THC	n	Placebo	Mean difference THC vs placebo (95% CI)
VRS interview					
Baseline	5	2.6 (1.3)	11	3.1 (1.8)	
Day 21	4	2.3 (1.0)	9	2.3 (1.0)	-0.03 (-1.0 to 0.9)
PACSLAC-D					
Baseline	8	8.4 (5.2)	15	7.2 (4.1)	
Day 21	7	7.4 (8.0)	13	6.2 (5.5)	-0.4 (-3.8 to 3.0)

Abbreviations: VRS, Verbal Rating Scale; PACSLAC-D, Pain Assessment Checklist for Seniors with Limited Ability to Communicate-Dutch version.

NOTE. Group numbers are means and standard deviations. Estimates of mean differences are based on linear mixed model analysis for repeated measures with participant as random effects for the subgroup of patients with pain. A negative mean difference favors THC for VRS and PACSLAC-D.

Table e-2. Study results of the application of THC on neuropsychiatric symptoms in dementia for all subdomains of Neuropsychiatric Inventory

	n	THC	n	Placebo	THC vs. placebo (95% CI)
NPI delusions					
Baseline	24	1.8 (3.0)	26	1.8 (3.3)	
Day 14	19	1.9 (3.6)	23	1.3 (2.6)	
Day 21	23	2.0 (3.5)	24	1.5 (2.7)	+0.7 (-0.5 to 1.9)
NPI hallucinations					
Baseline	24	0.8 (2.6)	26	0.3 (1.2)	
Day 14	19	0.3 (1.4)	23	0.3 (1.7)	
Day 21	23	0.0 (0.2)	24	0.3 (1.2)	-0.2 (-0.9 to 0.4)
NPI agitation/aggression					
Baseline	24	5.7 (3.8)	26	6.2 (4.3)	
Day 14	19	4.1 (4.7)	23	5.0 (3.9)	
Day 21	23	4.5 (4.1)	24	4.4 (4.3)	-0.1 (-2.0 to 1.9)
NPI dysphoria					
Baseline	24	2.9 (4.0)	26	3.4 (3.6)	
Day 14	19	1.6 (2.4)	23	2.1 (2.7)	
Day 21	23	2.3 (2.6)	24	1.8 (2.8)	0.0 (-1.0 to 1.1)
NPI anxiety					
Baseline	24	2.5 (4.0)	26	2.6 (3.7)	
Day 14	19	2.1 (3.5)	23	1.0 (2.6)	
Day 21	23	1.5 (2.8)	24	1.3 (2.3)	+0.5 (-0.7 to 1.8)
NPI euphoria					
Baseline	24	1.0 (2.5)	26	0.3 (0.9)	
Day 14	19	0.3 (1.4)	23	0.3 (1.7)	
Day 21	23	0.5 (1.3)	24	0.0 (0.2)	+0.1 (-0.5 to 0.6)
NPI apathy					
Baseline	24	5.0 (3.7)	26	2.5 (3.1)	
Day 14	19	5.1 (3.5)	23	2.4 (3.3)	
Day 21	23	4.1 (3.4)	24	2.3 (3.1)	+0.1 (-1.1 to 1.3)
NPI disinhibition					
Baseline	24	2.5 (3.3)	26	3.1 (3.4)	
Day 14	19	1.5 (2.6)	23	2.1 (3.0)	
Day 21	23	2.1 (3.2)	24	2.4 (3.4)	-0.1 (-1.6 to 1.4)
NPI irritability					
Baseline	24	5.3 (4.3)	26	5.7 (4.8)	
Day 14	19	5.1 (4.0)	23	4.2 (3.8)	
Day 21	23	4.3 (4.1)	24	3.9 (4.1)	+0.7 (-1.1 to 2.4)
NPI aberrant motor behavior					
Baseline	24	4.5 (4.6)	26	5.2 (4.1)	
Day 14	19	4.9 (4.0)	23	4.3 (4.2)	
Day 21	23	3.6 (3.9)	24	3.7 (4.3)	+0.3 (-1.0 to 1.7)
NPI nighttime behavior disturbances					
Baseline	24	2.5 (3.6)	26	2.5 (3.1)	

Day 14	19	1.4 (2.8)	23	2.2 (3.4)	
Day 21	23	0.8 (2.0)	24	1.8 (2.8)	-0.7 (-1.8 to 0.4)
NPI appetite and eating abnormalities					
Baseline	24	3.1 (4.0)	26	2.1 (3.4)	
Day 14	19	2.8 (3.8)	23	0.8 (1.9)	
Day 21	23	2.0 (3.0)	24	0.7 (1.6)	+1.0 (0.0 to 1.9)

Abbreviations: NPI, Neuropsychiatric Inventory

NOTE. Group numbers are means and standard deviations. Estimates of overall mean differences are based on linear mixed model analysis for repeated measures with participant as random effects. A negative mean difference favors THC for NPI subdomains.